Ideas
Software selloff looks overdone.
Last week's steep drop in software stocks looks overdone; the AI narrative has been too broad and there will be winners and losers, with many companies doing just fine.
Small caps rally on revisions, Fed cuts.
Small caps are having a moment: the Russell 2000 has rallied 21% over six months versus the S&P 500, Russell 2000 EPS revisions are up about 17% versus 9% for large caps, and if the Fed cuts several times this year that could be a more powerful catalyst for more levered small caps.
Software selloff overdone; fundamentals will step in.
The software selloff is overdone because software is embedded in clients' workflows for integration, governance, maintenance, and key feature updates; after a roughly 40% valuation rerating, fundamental buyers should step in and differentiate winners from losers, so the business is not permanently impaired.
Value and cyclical rotation underway.
A value and cyclical rotation is happening in the market, driven by economic fundamentals rather than just a momentum unwind.
Quest growth from prevention and diagnostics.
Quest Diagnostics is seeing growth from chronic disease management and from consumer prevention/wellness testing, where its consumer-health segment is about $250 million, grew over 30% last year, and is expected to grow north of 20%; Alzheimer's blood-based biomarkers and oncology/anatomical pathology and MRD testing add further growth drivers.
CVS outperform despite 2027 Medicare Advantage risk.
CVS is an outperform idea because 2026 remains on track for good growth and retail pharmacy has been a bright spot, but the 2027 Medicare Advantage rate notice makes the path less clean; CVS targets mid-teens EPS growth through 2028, yet half of that growth is Medicare Advantage, so inability to expand margins would materially impair the trajectory.
Medicare Advantage margins face knife fight.
Medicare Advantage plans face a difficult 2027: CMS rates are flat while cost trends are running high single digit to 10%, so even if the April rate improvement comes in around 100-150 basis points, it likely will not be enough; for CVS and most Medicare Advantage plans it may be a knife fight to keep margins flat rather than expand them.
Alignment Health bends cost curve.
Alignment Health is Baird's top pick because it bends the cost curve in a meaningful way, which should be a relative advantage as Medicare Advantage margins get squeezed.
BD reshapes portfolio, returns cash, targets growth.
Becton Dickinson had a strong quarter ahead of expectations, closed the Waters life-science merger to create a focused medtech company, reshaped the portfolio through three divestitures and 20 tuck-in acquisitions, will return value via a $2 billion ASR and debt paydown, and invests in growth areas including GLP-1 delivery, pharmacy robotics, and chronic disease technologies to support mid-single-digit growth.
Broadening favors equal-weight and small caps.
The rally has lacked tech leadership, but breadth has strengthened—two-thirds of NYSE companies are above their 200-day moving average—and cap-weighted index math works against the S&P when mega-cap tech, communication services, and consumer discretionary are not leading; equal-weight S&P and small caps can continue to outperform as the broadening extends.
Cyclicals benefit from reacceleration, weaker dollar.
Deeper cyclicals are likely keying off some reacceleration in parts of the U.S. economy, with manufacturing data looking better on the margin and a weaker dollar adding a tailwind for overseas sales.
Health care, staples are catch-up trades.
Health care and consumer staples are catch-up trades rather than a fundamental defensive call: differentials are starting to favor other parts of the market, margins may be improving at the margin, and these forgotten sectors could get some wind behind them.
Ford well positioned after taking near-term pain.
Ford is taking near-term tariff and EV-related pain now, but is well positioned for 2026 with hybrids, Ford Pro, the F-150, a pivot from EV batteries to battery storage for data centers and utilities, and cost reduction/vertical integration; 2025 sales rose 6%, above the industry's 2%, and the energy business is an underappreciated long-term driver.
Hinge Health has growth, moat, margin.
Hinge Health is a rare tech company with over $500 million of revenue, 50% revenue growth, and 30% free cash flow margin; AI has helped serve 50% more people at flat care costs, and the company still has a large runway with 90% of Americans lacking access to digital physical therapy, a $60 billion U.S. market, proprietary data, entrenched distribution, and clinical validation that should protect it from AI disruption.
Philips order intake and margins expanding.
Philips closed 2025 with 6% order intake growth that should convert into 3-4.5% growth in 2026 and step up to mid-single digits later; margins are expanding despite tariffs through productivity, mix, and AI-enabled innovations, and North America is a strong growth engine while China is stabilizing but not relied upon.
This Bloomberg Markets video, published February 11, 2026,
features David Solomon, Scarlet Fu, Niladri Mukherjee, Jim Davis, Michael Ha, Tom Polen, Kevin Gordon, Stephanie Valdez Streaty, Daniel Perez, Roy Jakobs
discussing IGV, IWM, Value stocks, XLI, DGX, CVS, Medicare Advantage insurers, ALHC, BDX, SP:SPXEW, XLV, XLP, F, Hinge Health, PHG.
15 trade ideas extracted by AI with direction and confidence scoring.
Speakers:
David Solomon,
Scarlet Fu,
Niladri Mukherjee,
Jim Davis,
Michael Ha,
Tom Polen,
Kevin Gordon,
Stephanie Valdez Streaty,
Daniel Perez,
Roy Jakobs
· Tickers:
IGV,
IWM,
Value stocks,
XLI,
DGX,
CVS,
Medicare Advantage insurers,
ALHC,
BDX,
SP:SPXEW,
XLV,
XLP,
F,
Hinge Health,
PHG
